Streetbeat News

Products Services

CHPT

ChargePoint has expanded its EV charging network to over one million locations across North America and Europe, facilitating more than 10 billion electric miles to date.

Portfolio Pulse from Benzinga Newsdesk

July 25, 2024 | 12:07 pm

OTRK

Ontrak announced significant savings from its WholeHealth+ program, with $721 PMPM savings over 24 months for graduates and $508 PMPM for non-graduates. The study validates the program's impact on reducing medical costs for a Medicaid health plan customer.

Portfolio Pulse from Benzinga Newsdesk

July 25, 2024 | 12:07 pm

VRDN

Viridian Therapeutics has completed enrollment for its THRIVE-2 phase 3 clinical trial for VRDN-001 in patients with chronic Thyroid Eye Disease (TED), exceeding its target with 188 patients. Topline data for THRIVE-2 is expected by year-end 2024, while data for the THRIVE trial is expected in September 2024.

Portfolio Pulse from Benzinga Newsdesk

July 25, 2024 | 12:05 pm

AQST

Aquestive Therapeutics has released topline pharmacokinetic (PK) data from its self-administration study of Anaphylm, showing comparable results whether administered by subjects or healthcare providers. The final Oral Allergy Syndrome (OAS) challenge study is currently enrolling, and a pre-New Drug Application (NDA) meeting is anticipated by the end of Q3 2024.

Portfolio Pulse from Benzinga Newsdesk

July 25, 2024 | 12:05 pm

VTAK

Catheter Precision, Inc. has completed the enrollment of 75 patients in its LockeT-II study, which is expected to conclude in October 2024.

Portfolio Pulse from Benzinga Newsdesk

July 25, 2024 | 12:04 pm

TNXP

Tonix Pharmaceuticals has received FDA Fast Track designation for its drug Tonmya, aimed at treating fibromyalgia. The company plans to submit a New Drug Application (NDA) in the second half of 2024. If approved, Tonmya could be the first new fibromyalgia drug in over 15 years.

Portfolio Pulse from Benzinga Newsdesk

July 25, 2024 | 12:03 pm

DOGEUSD

Dogecoin (DOGE) is gaining attention as analysts predict a potential bull run based on historical patterns. Technical chart analyst Ali Martinez notes that Dogecoin is following a pattern that could lead to a 44% upside. Despite a 15.6% drop in large transaction volume, daily active addresses have increased by 8.6%, and 72% of holders are in profit.

Portfolio Pulse from Khyathi Dalal

July 25, 2024 | 12:02 pm

ZVSA

ZyVersa Therapeutics, Inc. (NASDAQ: ZVSA) has selected obesity and related metabolic complications as the lead indication for its Inflammasome ASC Inhibitor IC 100. This decision marks a significant step in the company's development of first-in-class drugs for inflammatory and renal diseases.

Portfolio Pulse from Benzinga Newsdesk

July 25, 2024 | 12:00 pm

ENVB

Enveric Biosciences (NASDAQ:ENVB) announced positive preclinical results for its non-hallucinogenic psychedelic drug candidate EB-003, which can be administered orally. The company plans to advance EB-003 to clinical trials by the end of 2025. Enveric also recently obtained a US patent for another drug candidate, EB-002, aimed at treating neurological disorders.

Portfolio Pulse from Nina Zdinjak

July 25, 2024 | 12:00 pm

ETHE

FETH

GBTC

IBIT

Bitcoin and Ethereum experienced significant price drops, with Bitcoin falling over 3% and Ethereum plunging below $3,200. The decline was linked to a broader market downturn affecting U.S. technology stocks. Ethereum ETFs saw substantial outflows, while Bitcoin ETFs recorded mixed inflows and outflows.

Portfolio Pulse from Murtuza Merchant

July 25, 2024 | 11:54 am